The U.S. Food and Drug Administration (FDA) has reauthorized the marketing of IQOS as a modified risk tobacco product.

Philip Morris International (PMI) was the only company to obtain marketing authorization for heated tobacco products as modified risk products, according to the decision of the Food and Drug Administration (FDA). It concluded that the transition from conventional cigarettes to the IQOS system significantly reduces exposure to harmful chemicals.

The FDA renewed the authorization for two versions of the IQOS device and three variants of HEETS consumables, allowing PMI to communicate information about reduced exposure for adults in the U.S. Scientific evidence suggests that the IQOS system produces an aerosol with lower levels of harmful constituents compared to cigarette smoke.

PMI has invested over $16 billion to develop smoke-free products, with the ultimate goal of eliminating the sale of cigarettes. The company aims to support adult smokers in the transition to safer alternatives, promoting a smoke-free future.